Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nitric oxide inhalation - INOpulse - Mallinckrodt

Next Previous
X
Search
Drug Profile

Nitric oxide inhalation - INOpulse - Mallinckrodt

Alternative Names: Inhaled nitric oxide - Bellerophon; inhaled NO - Bellerophon; iNO- Bellerophon; Nitric oxide-INOpulse®

Latest Information Update: 07 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ikaria Holdings
  • Developer Bellerophon Therapeutics
  • Class Anti-infectives; Anti-inflammatories; Antiacnes; Antiandrogens; Antibacterials; Antibronchitics; Antifibrotics; Antifungals; Antihypertensives; Antineoplastics; Antituberculars; Antivirals; Cardiovascular therapies; Diagnostic agents; Foot disorder therapies; Free radicals; Nitrogen oxides; Non-opioid analgesics; Skin disorder therapies; Small molecules; Vascular disorder therapies; Vasodilators
  • Mechanism of Action Androgen receptor antagonists; Angiogenesis inducing agents; Cell death stimulants; Guanylate cyclase stimulants; Nitric oxide donors; Reactive oxygen species modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension; Idiopathic pulmonary fibrosis
  • New Molecular Entity No

Highest Development Phases

  • Phase III Pulmonary arterial hypertension; Pulmonary hypertension
  • Phase II Chronic obstructive pulmonary disease; Idiopathic pulmonary fibrosis
  • Discontinued COVID 2019 infections

Most Recent Events

  • 30 Jun 2023 Bellerophon Therapeutics terminates a phase III REBUILD trial in Pulmonary hypertension in Canada, USA (Inhalation) as the trial did not meet its primary endpoint (NCT03267108)
  • 05 Jun 2023 Efficacy and adverse events data from phase-III REBUILD trial in Pulmonary hypertension released by Bellerophon Therapeutics
  • 09 Feb 2023 National Medical Products Administration approves IND application for nitric oxide inhalation for a phase III trial in fibrotic Interstitial lung disease

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top